Table 2.
Electrode | Nanomaterial/Role | (Bio)sensing Approach/Format | Detection Technique | Target Analyte | LR/LOD | Sample | Ref. |
---|---|---|---|---|---|---|---|
-Magnetic carbon nanomaterials- | |||||||
CPE | m-CNTs@MIP/selective detection | Sensor | Voltammetry | Levofloxacin | 0.003–0.440 μM/0.8 nM. | Spiked serum, urine | [78] |
SPCE | m-MWCNTs/nanocarrier tag for Ab2 | Sandwich-type immunosensor | Amperometry (H2O2 + HQ) | Fetuin | 20–2000 pg mL−1/16 pg mL−1 | Saliva | [79] |
SPCE | AuNPs-Fe3O4-GS/electrode modifier | Aptasensor | SWV | CTCs | 5–500 cells mL−1/3–4 cells mL−1 | Whole blood | [80] |
GCE | Pb2+@AuNPs-MWCNTs-Fe3O4/label for Ab2 | Sandwich-type immunosensor | Amperometry (H2O2) |
AFP | 10 fg/mL–100 ng mL−1/3.33 fg mL−1 | Spiked serum | [81] |
AuE | Fe3O4/GO electrode modifier for avastin Ab1 immobilization | Label-free immunosensor | DPV [Fe(CN)6]3−/4− |
VEGF | 31.25–2000 pg mL−1 | Plasma | [82] |
GCE | Au@Ag/GS-Fe3O4/Cd2+/electrode modifier for immobilization of anti-IgG | Label-free immunosensor | Amperometry | IgG | 5 fg mL−1–50 ng mL−1/2 fg mL−1 | Serum | [83] |
SPCE | Fe3O4@AuNPs/NGr | Aptamer | DPV | Leukemia cancer cells | 10–106 cell mL−1 | Plasma | [84] |
ITO | Fe3O4@PDA/rGO/electrode modifier for Ab1 immobilization | Sandwich-type immunosensor | CV | MC-LR | 0.01–50 mg L−1/0.007 mg L−1 | Water | [85] |
GCE | GS-Fe3O4/Au@Ag/Ni2+/label for Ab2 loading | Sandwich-type immunosensor | Amperometry | CEA | 0.1 pg/mL–100 ng/mL/0.0697 pg/mL | Serum | [86] |
GCE | Fe3O4@AuNPs/rGO/electrode modifier for cortisol immobilization | Immunosensor/Direct competitive |
DPV (H2O2/HRP) |
Cortisol | 0.1–1000 ng mL−1/0.05 ng mL−1 | Serum | [87] |
CPE | Fe3O4/rGO-PANHS/electrode modifier for BRCA1 5382 insC ssDNA immobilization | Label-free DNA biosensor | EIS | BRCA1 5382 insC mutation. | 1.0 × 10−18–1.0 × 10−8 mol L−1/2.8 × 10−19 mol L−1 | Spiked genome samples | [88] |
GCE | CNP-L/CuONP/MWCNTs/Pe | Enzymatic biosensor | Amperometry | Triglycerides | 0.001–0.05 g L−1/0.0032 g L−1 (triolein) | Serum | [89] |
GCE | Fe3O4/CNTs/GO for aptamer immobilization | Label-free aptasensorr | DPV [Fe(CN)6]3−/4− |
Diclofenac | 100–1300 pM/ 33 pM |
Ampoules | [90] |
PtE | HRP/Fe3O4/Chit/rGO/electrode modifier | Enzymatic biosensor | CV | H2O2 | up to 100 μM | - | [91] |
SPCE | C@GNRs/electrode modifier for immobilization of ssDNA | DNA hybridization biosensor | CV Fe(CN)63− |
ssDNA | - | - | [92] |
GCE | ZnFe2O4/α-Fe2O3/Gr/electrode modifier | Non-enzymatic | Amperometric | Glucose | 1–10 mM | - | [93] |
GCE | Fe3O4@TMU-21/MWCNTs/electrode modifier | Label-free immunosensor | Amperometric (H2O2) |
HER2 | 1.0 pg mL−1–100 ng mL−1/0.3 pg mL−1 | Serum | [94] |
-Carbon nanozymes- | |||||||
GCE | ZnCr2O4/MWCNTs/electrode modifier | Enzyme-free sensor | Amperometry | H2O2 | 50 μM–34.8 mM/<0.11 μM | Lens cleaning solution | [95] |
GCE | RuNPs/MWCNTs-Av/HRP mimic nanozyme | Modified electrode | Amperometry | H2O2 | 5.0 × 10−7 M–1.75 × 10−3 M/65 nM | - | [96] |
GCE | Pt-DEN/CNTs/electrode modifier, HRP mimic nanozyme | Enzyme-free sensor | Amperometry | H2O2 | 3–400 μM/0.8 μM | H2O2 released from living cells | [97] |
GCE | Fe3O4/CNTs/GO/electrode modifier, HRP mimic nanozyme | Enzyme-free sensor and enzyme biosensor (GOx) |
CV (H2O2) Amperometry (glucose) |
H2O2, glucose |
0.01–0.50 mM (H2O2) 0.050–5.0 mM (glucose) |
- | [98] |
GCE | CDs/MWCNTs/electrode modifier, HRP mimic nanozyme | Enzyme-free sensor | Amperometry | H2O2 | 3.5 × 10−6–3.0 × 10−4 M/0.25 μM | H2O2 released from living cells, serum | [99] |
GCE | Au-Ag/MWCNTs/electrode modifier | Enzyme-free sensor | CV | Gastric cancer cells-volatile biomarkers | up to 0.0025% (v/v)/0.3 ppb (3-octanone), up to 0.055% (v/v)/0.5 ppb (butanone) | MGC-803, GES-1 cells |
[100] |
AuE | GQDs/electrode modifier, Ab1 immobilization, HRP mimic nanozyme | Label-free immunosensor | Amperometry | Yersinia enterecolitica | 6.23 × 102–6.23 × 108 cfu mL−1/5 cfu mL−1 (milk), 30 cfu mL−1 (serum) | Milk, serum | [101] |
SPCE | GDQs/MWCNTs/Ab2 and HRP nanocarrier, HRP mimic nanozyme | Sandwich-type immunosensor | Amperometry (H2O2, HQ) |
IL-13Rα2 | 2.7–100 ng mL−1/0.8 ng mL−1 | Raw cellular lysates | [102] |
GCE | PtPd/N-GQDs@Au/electrode modifier/catalytic activity towards H2O2 | Label-free immunosensor | Amperometry (H2O2) |
CEA | 5 fg mL−1–50 ng mL−1/2 fg/mL | Spiked serum | [103] |
AuE | GQDs/HRP mimic nanozyme | Enzyme-free sensor | Amperometry | H2O2 | - | Human breast cancer MCF-7 cells | [104] |
GCE | Au/OMCS/electrode modifier/xanthine oxidase mimics | Enzyme-free sensor | DPV | Xanthine | 0.10–20 μM/0.006 μM | Spiked urine | [105] |
-Multifunctional biomedical applications- | |||||||
AuE | rGO/insulin/Ni(OH)2/insulin releasing, glucose detection | Enzyme-free sensor | Amperometry | Glucose | 5 μM–10 mM/~ 5 μM | - | [106] |
GCE | rGO/PdNFs/electrode modifier | Enzyme-free sensor | Amperometry | Glucose | 10–90 nM/8 nM | - | [107] |
Au/PO | Gr/electrode modifier | Flexible microsensor | DPV | Dopamine | 0.3 μM to 56.8 μM/0.11 μM | - | [108] |
CPE | PVC/rGO/AuNPs/CNT/electrode modifier | Dual microcatheter | SWV | Propofol, fentanyl |
25–125 μM (PPF), 10–50 nM (FTN) | Whole blood | [109] |
GCE | rGO/MB-AuNPs/electrode modifier, immobilization of aptamer-Fc | Ratiometric aptasensor | SWV | VEGF | 2–500 pg mL−1/0.1 pg mL−1 | Serum | [110] |
GCE | rGO/MB/electrode modifier | Ratiometric sensor | DPV | Cerebral ascorbic acid | 0.5 μM–1000 μM/ 10 nM |
Brain micro-dialysate | [111] |
needle-type electrode | rGO/AuNCs/immobilization of ssDNA | Micro-aptasensor (hybridization) |
DPV (MB) |
Adenosine | 0.1 nM–1 mM/~0.1 nM | In vivo (rat body) |
[112] |
micro-electrode array | rGOPtNPs/electrode modifier | Microsensor | DPV | Norepinephrine | -/0.08 μM | Brain silice secretion | [113] |
GCE | rGO-MWCNTs /Chit/CQDs/aptamer immobilization |
Label-free aptasensor | DPV, EIS [Fe(CN)6]3−/4− |
Lysozyme | 20 fmol L−1–10 nmol L−1/3.7 fmol L−1 (DPV); 10 fmol L−1–100 nmol L−1/1.9 fmol L−1 (EIS) |
Spiked serum, urine | [114] |
-Multifunctional carbon nanomaterials for signal amplification- | |||||||
SPCE | V-Phe-SWCNT (-HRP)/carrier tag for immobilization of Ab2 |
Sandwich-type immunosensor | Amperometry | TGF-β1 | 2.5–1000 pg mL−1/0.95 pg mL−1 | Saliva | [115] |
AuE | COOH-MWCNTs/AuNPs/immobilization of thionine and aptamer | Aptasensor | DPV | Tetracycline | 0.1 nM–1 μM/0.06 nM | - | [116] |
GCE | AuNPs-rGO/electrode modifier and Ab1 immobilization; SWCNTs-GQDs/carrier tag for Ab2 immobilization | Sandwich-type immunosensor | SWV (H2O2) |
CEA | 50–650 pg mL−1/5.3 pg mL−1 | Spiked serum | [117] |
GCE | Pt@Au-P-C60-rGO electrode modifier for immobilization of SH-aptamer and GOx | Label-free aptasensor | CV | Sulfadime-thoxime | 10−5–50 ng mL−1/8.68 fg mL−1 | Spiked milk | [118] |
GCE | Pd/g-C3N4-CNTs/electrode modifier | Sensor | DPV | EE2 | 2.0 × 10−6 –1.5 × 10−4 M/5.0 × 10−7 M | Chicken and pig foodstuffs | [119] |
GCE | GOx/Au/MXene/Nafion | Enzyme biosensor | Amperometry | glucose | 0.1–18 mM/5.9 μM | - | [120] |
AuNPs/ GCE | c-g-C3N4/carrier tag for Ab2 immobilizantion | Sandwich-type immunosensor | DPV | Procalcitonin | 0.01–1.0 pg mL−1/2.0 fg mL−1 | Plasma | [121] |
dSPCE | GQDs/MWCNTs/HRP, carrier tag for Ab2 immobilization | Dual sandwich-type immunosensor | Amperometry (H2O2, HQ) |
IL-13Rα2, CDH-17 |
4.92–100 ng mL−1/1.4 ng mL−1 (IL-13sRα2); 0.11–10 ng mL−1/0.03 ng mL−1 (CDH-17) |
Lysates from breast and colorectal cancer cells | [122] |
GCE | Chit@AB-MWCNTs/AuNPs/electrode modifier for immobilization of aptamer and specific binding to GO-ZEN Apt. | Aptasensor | DPV ([Fe(CN)6]3−/4−) |
ZEN | 10 fg mL−1–1 ng mL−1/ 3.64 fg mL−1 |
Corn oil and corn flour | [123] |
AFP: alpha-fetoprotein; CDH-17: cadherin-17; CEA: carcinoembryonic antigen; C@GNRs: carbon-graphene nanoribbons; Chit: chitosan; CNP-L: lipase immobilized on magnetic nanoparticles; CQDs: carbon quantum dots; CTCs: circulating tumor cells; CPE: carbon paste electrode; CTCs: circulating tumor cells; CuONP: cupric oxide nanoparticles; CV: cyclic voltammetry; EE2: 17α-ethinylestradiol; EIS: electrochemical impedance spectroscopy; Fe3O4@TMU-21: magnetic framework TMU-21; GCE: glassy carbon electrode; GN: graphene nanosheet; GO: graphene oxide; GOx: glucose oxidase; GQDs: graphene quantum dots; GS: graphene sheets; HER2: human epidermal growth factor receptor 2; HRP: horseradish peroxidase; IL-13Rα2: receptor α2 of interleukin-13; ITO: indium tin oxide; MB: methylene blue; LOD: detection limit; m-CNTs: magnetic carbon nanotubes; MC-LR: microcystin-LR; OMCS: ordered mesoporous carbon/silica; NGr: nitrogen doped graphene; PANHS: polycyclic aromatic nitrogen heterocycles; Pe: pectin; SPCE: screen-printed carbon electrode; P-C60: poly(diallyldimethylammonium chloride)-fullerene C60; PdNFs, paladium nanoglowers; PO: poluolefin; SWV: square wave voltammetry; TGF-β1: transforming growth factor-β1; VEGF: vascular endothelial growth factor; ZEN: zerealenone.